Two patients each went from over 90 large polyps to one
Recursion (RXRX) reported positive Phase 2 data from the TUPELO trial of REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). After 12 weeks, patients saw a 47% median reduction in polyp burden, with 85% remaining below baseline 12 weeks post-treatment. Two patients reduced their larger polyp counts from over 90 to one. No new safety signals were observed. The company plans to initiate a registrational trial in 2027, pending FDA discussions.
How this was made
The 30-second read
Why it matters
The data suggest a strong proof‑of‑concept, potentially accelerating FDA discussions and boosting the company's valuation.
Market read
First‑report positive Phase 2 data for a small‑cap biotech, likely to move RXRX and influence sector sentiment.
What to watch
Regulatory timeline uncertainty and competition from other FAP therapies could limit upside.
Background
Recursion announced updated Phase 2 results for REC-4881, an oral MEK1/2 inhibitor, showing median 47% reduction in polyp burden and deep reductions in larger polyps.
Ticker impact
Recursion (RXRX) released new positive Phase 2 data for its oral MEK inhibitor REC-4881 in familial adenomatous polyposis.
potential upside as market prices in the favorable Phase 2 data
The data are first‑report, material clinical‑trial news for a small‑cap biotech, which typically moves the stock sharply.
Market effects
Strengthens the biotech sector's pipeline outlook for GI‑targeted therapies.
US biotech investors may increase exposure to early‑stage oncology/ GI drugs.
May attract interest from global investors tracking novel cancer prevention treatments.
Counterpoint
If the durability of the response wanes in longer trials, the initial hype could reverse.
Key entities
- companyRecursion
Clinical‑stage biotech developing AI‑driven drug discovery.
- drugREC-4881
Oral MEK inhibitor targeting familial adenomatous polyposis.
